With the wind of the pandemic at its back, the biopharma industry saw a surging tide of fundraising in 2020 that has only exponentially grown this year, Enpoint News writes. But with VC dollars flowing like never before, are there some cracks showing in biopharma’s gold-tinted façade? In the first half of 2021, total healthcare venture spending in the US has already outstripped 2020’s record-breaking totals across biotech, healthtech and beyond, putting the industry on a funding pace that could be hard to match in coming years, according to a new report from Silicon Valley Bank released Wednesday. Read more.
Related Posts
Investment Activity in the Skilled Nursing Sector is Ramping Back Up
nvestors paid an average of $93,000 per bed for skilled nursing facilities in 2021, according to data from Real Capital Analytics, based in New York City. That’s 10 percent higher than the previous year.
May 24, 2022
VC Valuations Extend Slump as Down Rounds Creep up in Q1
The median deal size for late-stage rounds fell 25% to $6 million, the lowest figure recorded since Q2 2017.
May 11, 2023
Investors are “Head Over Heels” for Orthopaedics: Report
Over the past several years, even throughout the slower months of early 2020 during the COVID-19 pandemic, orthopaedic deals have been highly sought after and highly competitive.
August 30, 2021
The 10 Mental Health Tech Unicorns with the Highest Valuations in 2021
The mental health tech space raised $5 billion and created nine new mental health unicorns in 2021, according to new data from CB Insights.
March 2, 2022